Ceftazidime
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceftazidime: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum gram-negative bactericidal activity, widely used for serious bacterial infections including urinary tract infections, pneumonia, and septicemia. The TxGNN model predicts it may be effective for Hyperamylasemia, with 0 clinical trials and 1 publication currently supporting this direction. The mechanistic link is highly indirect, and the available evidence is insufficient to advance this prediction beyond an exploratory stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Broad-spectrum bacterial infections (no Saudi Arabia registration on record) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L4 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, ceftazidime is a third-generation cephalosporin β-lactam antibiotic; its efficacy in treating serious gram-negative bacterial infections — including those caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli — has been well established in clinical practice, and mechanistically it may be applicable to conditions where secondary bacterial infection triggers an inflammatory cascade leading to serum amylase elevation.
Hyperamylasemia is a biochemical marker (elevated serum amylase) rather than an independent disease entity. It most commonly signals acute pancreatitis or post-ERCP complications. The theoretical link between ceftazidime's antibacterial mechanism and serum amylase reduction is indirect: preventing bacterial translocation or bacteremia could theoretically limit the pancreatic inflammatory response that drives amylase release — but this causal chain has not been directly studied.
The sole supporting literature (PMID 11985972) evaluates whether routine prophylactic antibiotics — as a multimodal regimen, not ceftazidime specifically — reduce the incidence of post-ERCP pancreatitis. The study does not designate hyperamylasemia as a primary endpoint, and ceftazidime's individual contribution is indistinguishable from the combined antibiotic effect. The mechanistic connection therefore remains weak and inferential.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11985972 | 2001 | RCT (multi-antibiotic scheme; ceftazidime not studied in isolation) | Journal of Gastrointestinal Surgery | Prospective study evaluating whether prophylactic antibiotics reduce post-ERCP cholangitis and pancreatitis; provides indirect evidence that antibiotic prophylaxis may limit amylase-elevating inflammatory events, but does not assess ceftazidime as the active agent nor hyperamylasemia as a primary endpoint |
Saudi Arabia Market Information
No authorizations registered in Saudi Arabia.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Hyperamylasemia is a biochemical surrogate marker rather than a discrete therapeutic target, and the only supporting evidence is a single multi-antibiotic RCT that does not isolate ceftazidime's effect nor designate amylase elevation as a primary endpoint — this is insufficient mechanistic or clinical basis to proceed.
To proceed, the following is needed:
- Mechanism of action data (MOA) from DrugBank to characterize whether any off-target pharmacology could influence pancreatic enzyme release
- Safety data (key warnings, contraindications) retrieved from the package insert PDF
- Reconsideration of whether the more appropriate clinical framing is post-ERCP pancreatitis prevention rather than hyperamylasemia per se, which would require a dedicated prospective study with amylase level as a co-primary endpoint
- Assessment of whether the higher-evidence indications in this evidence pack — particularly urinary tract infection (L2, Proceed with Guardrails) and infectious otitis media (L3, Proceed with Guardrails) — should be prioritized over this rank-1 prediction for regulatory and clinical development purposes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.